Using Real‐World Evidence for Clinical Development to Address the Gap Between Marketing Authorisation and Reimbursement in European Countries: Insights From Literature Review.
Background: Health Technology Assessment (HTA) agencies require evidence relevant to elements like the 'added value' of the drug, efficacy and safety in real life, or data regarding the drugs' effects on different subgroups of interest. Using Real‐World Evidence (RWE) during drug clinical developmen...
| Publicado en: | Journal of Evaluation in Clinical Practice Vol. 31; no. 3; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Apr2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |